

Ref.

G-5023

1. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *Jama*. Oct 23-30 2002;288(16):2015-2022. PMID 12387654
2. Peng HY, Man CF, Xu J, et al. Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: a meta-analysis of prospective studies. *J Zhejiang Univ Sci B*. Jan 2015;16(1):78-86. PMID 25559959
3. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation*. Jul 21 1998;98(3):204-210. PMID 9697819
4. Evans RW, Shaten BJ, Hempel JD, et al. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. *Arterioscler Thromb Vasc Biol*. Oct 1997;17(10):1947-1953. PMID 9351358
5. Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. *Arch Intern Med*. Apr 27 1998;158(8):862-867. PMID 9570171
6. Shoamanesh A, Preis SR, Beiser AS, et al. Circulating biomarkers and incident ischemic stroke in the Framingham Offspring Study. *Neurology*. Sep 20 2016;87(12):1206-1211. PMID 27558379
7. Han L, Wu Q, Wang C, et al. Homocysteine, ischemic stroke, and coronary heart disease in hypertensive patients: a population-based, prospective cohort study. *Stroke*. Jul 2015;46(7):1777-1786. PMID 26038522
8. Wang C, Han L, Wu Q, et al. Association between homocysteine and incidence of ischemic stroke in subjects with essential hypertension: A matched case-control study. *Clin Exp Hypertens*. Nov 2015;37(7):557-562. PMID 25992490
9. Catena C, Colussi G, Nait F, et al. Elevated homocysteine levels are associated with the metabolic syndrome and cardiovascular events in hypertensive patients. *Am J Hypertens*. Jul 2015;28(7):943-950. PMID 25498997
10. Sheng L, Wu C, Bai YY, et al. Plasma homocysteine levels are independently associated with alterations of large artery stiffness in men but not in women. *J Geriatr Cardiol*. May 2015;12(3):251-256. PMID 26089849
11. Shi Z, Guan Y, Huo YR, et al. Elevated total homocysteine levels in acute ischemic stroke are associated with long-term mortality. *Stroke*. Sep 2015;46(9):2419-2425. PMID 26199315
12. Wang CY, Chen ZW, Zhang T, et al. Elevated plasma homocysteine level is associated with ischemic stroke in Chinese hypertensive patients. *Eur J Intern Med*. Jul 2014;25(6):538-544. PMID 24824758
13. Park CS, Ihm SH, Yoo KD, et al. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. *Am J Cardiol*. May 1 2010;105(9):1284-1288. PMID 20403480

14. Ma Y, Li L, Geng XB, et al. Correlation between hyperhomocysteinemia and outcomes of patients with acute myocardial infarction. *Am J Ther.* Nov/Dec 2016;23(6):e1464-e1468. PMID 25405897
15. Veeranna V, Zalawadiya SK, Niraj A, et al. Homocysteine and reclassification of cardiovascular disease risk. *J Am Coll Cardiol.* Aug 30 2011;58(10):1025-1033. PMID 21867837
16. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med.* Jul 24 1997;337(4):230-236. PMID 9227928
17. Knekt P, Reunanen A, Alfthan G, et al. Hyperhomocysteinemia: a risk factor or a consequence of coronary heart disease? *Arch Intern Med.* Jul 9 2001;161(13):1589-1594. PMID 11434790
18. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med.* May 13 1999;340(19):1449-1454. PMID 10320382
19. Park JH, Saposnik G, Ovbiagele B, et al. Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: A meta-analysis. *Int J Stroke.* Feb 2016;11(2):206-211. PMID 26783312
20. Marti-Carvajal AJ, Sola I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev.* Jan 31 2013;1(1):CD006612. PMID 23440809
21. Marti-Carvajal AJ, Sola I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev.* Jan 15 2015;1:CD006612. PMID 25590290
22. Yi X, Zhou Y, Jiang D, et al. Efficacy of folic acid supplementation on endothelial function and plasma homocysteine concentration in coronary artery disease: A meta-analysis of randomized controlled trials. *Exp Ther Med.* May 2014;7(5):1100-1110. PMID 24940394
23. Liu Y, Tian T, Zhang H, et al. The effect of homocysteine-lowering therapy with folic acid on flow-mediated vasodilation in patients with coronary artery disease: a meta-analysis of randomized controlled trials. *Atherosclerosis.* Jul 2014;235(1):31-35. PMID 24814647
24. Huang T, Chen Y, Yang B, et al. Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. *Clin Nutr.* Aug 2012;31(4):448-454. PMID 22652362
25. Zhou YH, Tang JY, Wu MJ, et al. Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis. *PLoS One.* Oct 2011;6(9):e25142. PMID 21980387
26. Clarke R, Halsey J, Bennett D, et al. Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials. *J Inher Metab Dis.* Feb 2011;34(1):83-91. PMID 21069462
27. van Dijk SC, Enneman AW, Swart KM, et al. Effects of 2-year vitamin B12 and folic acid supplementation in hyperhomocysteinemic elderly on arterial stiffness and cardiovascular outcomes within the B-PROOF trial. *J Hypertens.* Sep 2015;33(9):1897-1906; discussion 1906. PMID 26147383

28. Study of the Effectiveness of Additional Reductions in Cholesterol Homocysteine Collaborative Group, Armitage JM, Bowman L, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. *Jama*. Jun 23 2010;303(24):2486-2494. PMID 20571015
29. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med*. Apr 13 2006;354(15):1567-1577. PMID 16531613
30. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med*. Apr 13 2006;354(15):1578-1588. PMID 16531614
31. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. *J Thromb Haemost*. Feb 2005;3(2):292-299. PMID 15670035
32. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. *Thromb Haemost*. Dec 1998;80(6):874-877. PMID 9869152
33. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. *Arch Intern Med*. Oct 26 1998;158(19):2101-2106. PMID 9801176
34. Keijzer MB, Borm GF, Blom HJ, et al. No interaction between factor V Leiden and hyperhomocysteinemia or MTHFR 677TT genotype in venous thrombosis. Results of a meta-analysis of published studies and a large case-only study. *Thromb Haemost*. Jan 2007;97(1):32-37. PMID 17200768
35. Naess IA, Christiansen SC, Romundstad PR, et al. Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population--results from the HUNT 2 study. *Br J Haematol*. May 2008;141(4):529-535. PMID 18318759
36. Zhou K, Zhao R, Geng Z, et al. Association between B-group vitamins and venous thrombosis: systematic review and meta-analysis of epidemiological studies. *J Thromb Thrombolysis*. Nov 2012;34(4):459-467. PMID 22743781
37. den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. *Blood*. Jan 1 2007;109(1):139-144. PMID 16960155
38. Ray JG, Kearon C, Yi Q, et al. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. *Ann Intern Med*. Jun 5 2007;146(11):761-767. PMID 17470822
39. National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification [CG181]. 2016; <https://www.nice.org.uk/guidance/cg181/chapter/1-Recommendations#identifying-and-assessing-cardiovascular-disease-cvd-risk-2>. Accessed November 2, 2018.
40. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. Dec 2014;45(12):3754-3832. PMID 25355838

41. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* Jul 1 2014;63(25 Pt B):2935-2959. PMID 24239921
42. Myers GL, Christenson RH, Cushman M, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. *Clin Chem.* Feb 2009;55(2):378-384. PMID 19106185
43. Maynard G. Preventing hospital-associated venous thromboembolism: a guide for effective quality improvement. 2nd ed. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
44. National Institute for Health and Care Excellence (NICE). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. 2018; <https://www.nice.org.uk/guidance/ng89>. Accessed November 2, 2018.
45. U.S. Preventive Services Task Force. Coronary Heart Disease: Screening Using Non-Traditional Risk Factors. 2009; <http://www.uspreventiveservicestaskforce.org/uspstf/uspscoronaryhd.htm>. Accessed November 2, 2018.
46. U.S. Preventive Services Task Force. Cardiovascular Disease: Risk Assessment Using Nontraditional Risk Factors. 2018; <https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/cardiovascular-disease-screening-using-nontraditional-risk-assessment?ds=1&s=nontraditional>. Accessed November 2, 2018.